Sensorion Enrolls Last Patient in Clinical Trial of Drug to Prevent Cisplatin-Induced Ototoxicity
Sensorion has completed patient enrollment for its Phase 2a NOTOXIS trial, evaluating SENS-401’s potential to prevent Cisplatin-induced ototoxicity.
Read More